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DNGR-1 is required for cross-priming but not for cross-tolerance to dead cell–associated antigens. (A) WT mice were left untreated or were 
injected with UV-treated H-2bm1 OVA-expressing MEFs i.v. One week later mice received B16-OVA cells i.v., and the number of tumors per 
lung was determined after 18 days. Data are representative of 2 independent experiments (n = 6/group, each dot represents 1 mouse). (B) WT 
(n = 16), DNGR-1–deficient (n = 11), or IAα–/– (n = 6) mice were injected with UV-treated H-2bm1 OVA–expressing MEFs, and the percentage of 
H2-Kb-OVA tetramer+ cells among CD8+ T cells in blood was determined 7 days after injection. Data were pooled from 2 independent experi-
ments; each dot represents 1 mouse. (C) WT or DNGR-1–deficient mice received CFSE-labeled CD45.1+ OT-I cells, followed by immunization 
with UV-treated OVA-MEFs 1 day later. Spleens were analyzed 5 days after immunization for OT-I proliferation. CFSE dilution (left panel) and 
total number of divided cells (right panel) are shown; each dot represents 1 mouse. (D) DNGR-1–sufficient or DNGR-1–deficient RIP-mOVA mice 
received CFSE-labeled CD45.1+ OT-I cells. Renal LNs were analyzed 3 days after injection for OT-I proliferation quantified by CFSE dilution 
(left panel) and total number of divided cells (right panel); each dot represents 1 mouse. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired Student’s 
t test and 1-way ANOVA (Tukey’s post-test).
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DNGR-1 does not behave as 
a myeloid activatory recep-
tor. BM cells from Dectin-
1–deficient mice were ret-
rovirally transduced with a 
vector encoding for Dectin-1 
or for a chimeric receptor 
(Chimera) bearing the cyto-
plasmic tail of DNGR-1 (WT) 
or 3 mutant versions thereof 
(Y7F, A3D, and I6G) fused 
to the transmembrane, stalk 
region, and CTLD of Dec-
tin-1. All constructs were 
followed by an IRES-GFP 
sequence, which allowed 
sorting based on GFP levels 
to normalize for Dectin-1 or 
chimera surface expression. 
(A) Schematic representa-
tion of the chimeric DNGR-1/
Dectin-1 receptors. Asterisks 
denote the mutated residues. 
(B) Expression of Dectin-1 
or the different chimeras 
by GFP+ GMCSF-BMDCs 
purified by cell sorting as 
determined by staining with 
an anti–Dectin-1 antibody 
before overnight stimulation. 
(C) Purified GFP+ DCs as in 
B were cultured overnight in 
the presence of increasing 
amounts of curdlan (0, 30, 
and 100 μg/ml). Concentra-
tions of TNF-α, IL-2, and 
IL-10 in the supernatant after 
culture are shown. Results 
are mean ± SEM and repre-
sentative of at least 3 inde-
pendent experiments. ND, 
not detected.
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DNGR-1 regulates MHC class I cross-presentation but not MHC class II presentation of dead cell–associated antigens. (A) The adjuvanticity 
of dead cells is independent of DNGR-1. Purified CD8α+-like Flt3L-BMDCs from WT or DNGR-1–deficient (Clec9agfp/gfp) mice were pulsed 
with 1 pM SIINFEKL peptide, washed, and cultured with UV-treated H-2bm1 MEFs and CFSE-labeled OT-I T cells. OT-I proliferation was 
quantified after 3 days. (B and C) DNGR-1 regulates cross-presentation of dead cell–associated antigens. Purified CD8α+-like Flt3L-BMDCs 
from WT or DNGR-1–deficient mice were cultured with UV-treated OVA-MEFs or latex beads coated with OVA (OVA beads). Proliferation of 
CFSE-labeled OT-I (B) or OT-II (C) T cells was quantified on day 3 or 5 (respectively) of coculture with DCs. (D) Purified CD8α+-like Flt3L-
BMDCs from WT, DNGR-1–deficient, or Tap1–/– mice were cultured with UV-treated OVA-MEFs and B3Z cells. NFAT reporter activity in B3Z 
cells was measured using a colorimetric assay after 24 hours of coculture. Results are mean ± SD and representative of at least 3 indepen-
dent experiments. *P < 0.05, **P < 0.01, unpaired Student’s t test.
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DNGR-1 diverts cargo to the early/recycling endosomal pool. (A) 
Purified splenic CD8α+ DCs from WT mice were cultured for 30 min-
utes (EEA-1) or for 90 minutes (Rab5a and Rab27a) with Alexa Fluor 
488–coupled anti–DNGR-1 Ab. Cells were fixed and stained for confo-
cal microscopy. Distribution of internalized anti–DNGR-1 Ab+ vesicles 
relative to EEA-1+, Rab5a+, or Rab27a+ vesicles was quantified as per-
centage of vesicles positive for anti–DNGR-1 antibody also positive 
for endosomal markers in 15 cells per condition. (B and C) Purified 
CD8α+-like Flt3L-BMDCs from WT or DNGR-1–deficient mice were 
cultured with UV-treated Alexa Fluor 647–labeled H-2bm1 MEFs. Cells 
were fixed after 60 or 240 minutes and stained for confocal microsco-
py. Distribution of cargo derived from dead cells relative to Rab5a (B) 
and Rab11 (C) was quantified as percentage of total vesicles positive 
for endosomal markers containing dead cell cargo in 15 cells per con-
dition. Scale bars: 5 μm. Results are representative of 2 independent 
experiments. *P < 0.05, **P < 0.01, unpaired Student’s t test.
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SFV-OVA–infected cells induce TLR3-dependent DC activation and 
DNGR-1–dependent cross-presentation. Purified CD8α+-like Flt3L-
BMDCs from WT, DNGR-1–deficient, or Tlr3–/– mice were cultured with 
SFV-OVA–infected H-2bm1 MEFs (infected cells) at the indicated ratios 
in the absence (A) or presence (B) of CFSE-labeled OT-I T cells. (A) 
Concentration of IL-6 and TNF-α in the supernatant (upper panels) and 
MFI of CD86 and CD40 surface expression (lower panels) after over-
night culture. As a positive control, DCs were cultured in the presence 
of CpG (500 ng/ml). Results are mean ± SEM and representative of 2 
independent experiments. (B) OT-I proliferation was quantified after 3 
days. Results are mean ± SEM and representative of at least 3 inde-
pendent experiments. *P < 0.05, **P < 0.01, unpaired Student’s t test.
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DNGR-1 contributes to the CTL response to HSV-1 lung infection. WT, DNGR-1–deficient, or Batf3–/– mice were infected with HSV-1 i.n. 
Mediastinal LNs were harvested 7 days later, and CTL responses were measured directly ex vivo or after in vitro restimulation. (A) Left panel: 
H-2Kb-gB pentamer+ cells as a percentage of CD8+CD44+ T lymphocytes. Right panel: Number of H-2Kb-gB pentamer+CD8+CD44+ T cells. 
(B) IFN-γ+ cells as a percentage of CD8+CD44+ T lymphocytes after restimulation with gB498–505 peptide for 6 hours. Data were pooled from 3 
independent experiments, with each dot representing 1 mouse; naive WT, n = 5; WT, n = 13; DNGR-1–deficient, n = 13, Batf3–/–, n = 8 mice. 
*P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA (Tukey’s post-test).
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